Transgene Biotek Limited

Company Profile

Transgene Biotek Limited had its IPO on under the ticker symbol 526139.

The company operates in the Other sector and Other industry. Transgene Biotek Limited has a staff strength of 0 employees.

Stock update

Shares of Transgene Biotek Limited opened at ₹4.5 at the start of the last trading session i.e. 2023-09-13.

The stocks traded within a range of ₹4.28 - ₹4.69, and closed at ₹4.36.

This is a -2.46% slip from the previous day's closing price.

A total volume of 42,409 shares were traded at the close of the day’s session.

In the last one week, shares of Transgene Biotek Limited have slipped by -0.68%.

Transgene Biotek Limited's Key Ratios

Transgene Biotek Limited has a market cap of ₹308.38 million, indicating a price to book ratio of 1.0459 and a price to sales ratio of 9557.6075.

In the last 12-months Transgene Biotek Limited’s revenue was ₹-34940 with a gross profit of ₹-145632 and an EBITDA of ₹0. The EBITDA ratio measures Transgene Biotek Limited's overall financial performance and is widely used to measure its profitability.

In the trailing 12-month period, Transgene Biotek Limited’s operating margin was 304918.63% while its return on assets stood at -3.99% with a return of equity of -32.86%.

In Q3, Transgene Biotek Limited’s quarterly earnings growth was a positive 0% while revenue growth was a positive 0%.

Transgene Biotek Limited’s PE and PEG Ratio

Forward PE

0

Trailing PE

0

PEG

Its diluted EPS in the last 12-months stands at ₹-1.42 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.

The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Transgene Biotek Limited’s profitability.

Transgene Biotek Limited stock is trading at a EV to sales ratio of 12434.9874 and a EV to EBITDA ratio of 0. Its price to sales ratio in the trailing 12-months stood at 9557.6075.

Transgene Biotek Limited stock pays annual dividends of ₹ per share, indicating a yield of None and a payout ratio of 0%.

Balance sheet and cash flow metrics

Total Assets

₹1.42 billion

Total Liabilities

₹104.67 million

Operating Cash Flow

₹-123010.00

Capital Expenditure

₹108350

Dividend Payout Ratio

0%

Transgene Biotek Limited ended 2024 with ₹1.42 billion in total assets and ₹0 in total liabilities. Its intangible assets were valued at ₹1.42 billion while shareholder equity stood at ₹113.69 million.

Transgene Biotek Limited ended 2024 with ₹0 in deferred long-term liabilities, ₹104.67 million in other current liabilities, 757700010.00 in common stock, ₹-644012000.00 in retained earnings and ₹0 in goodwill. Its cash balance stood at ₹700.00 and cash and short-term investments were ₹30520.00. The company’s total short-term debt was ₹81,621,010 while long-term debt stood at ₹49.50 million.

Transgene Biotek Limited’s total current assets stands at ₹8.94 million while long-term investments were ₹0 and short-term investments were ₹0. Its net receivables were ₹84460.00 compared to accounts payable of ₹0 and inventory worth ₹337600.00.

In 2024, Transgene Biotek Limited's operating cash flow was ₹-123010.00 while its capital expenditure stood at ₹108350.

Comparatively, Transgene Biotek Limited paid ₹0 in dividends in 2024.

Other key metrics

Current Trading Price

₹4.36

52-Week High

₹5.09

52-Week Low

₹2.28

Analyst Target Price

₹

Transgene Biotek Limited stock is currently trading at ₹4.36 per share. It touched a 52-week high of ₹5.09 and a 52-week low of ₹5.09. Analysts tracking the stock have a 12-month average target price of ₹.

Its 50-day moving average was ₹4.08 and 200-day moving average was ₹3.32 The short ratio stood at 0 indicating a short percent outstanding of 0%.

Around 2165% of the company’s stock are held by insiders while 0% are held by institutions.